News | August 07, 2024
Bayer Group posts 2Q 2024 sales up 3.1% at € 11.14 billion
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
Pharmaceuticals and Consumer Health report higher sales (Fx & portfolio adj.) and lower earnings
He advocated for a "PPP + PPP" collaboration, urging the public and private sectors within India to partner with their counterparts in other countries
Lonza Bend (US) upgrades capabilities in early phase clinical manufacturing services with the addition of bottling and labeling equipment
Both departments will be equipped with specialized professionals and state-of-the-art facilities ensuring the highest standards of care
The successful completion of the global Phase 3 trials paves the way to obtain marketing approval in the U.S. and EU
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
Dr. Vinod Kumar Paul highlighted the huge gap between the demand for and supply of organs
Emraclidine, a potential best-in-class, next-generation antipsychotic, is in trials designed to be registration enabling for schizophrenia
Q1 FY25 revenues up 20% YoY to Rs. 1,002 crore
Q1 Consolidated operating profit Up 8.3%; revenue grows 7% to Rs 3,349 crore
Subscribe To Our Newsletter & Stay Updated
